Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That quick pop at open didn't last long.
If I'm not mistaken the German treatment is not DCvax. It was covered here several months ago.
Wow. It's the nwbo negative spin zone. Lol
Interesting
The primary study endpoint is OS (overall survival) compared to external controls in newly diagnosed glioblastoma, and the first secondary endpoint is OS compared to external controls in recurrent glioblastoma
The fact that pharma provides a large part of the FDA's budget is all I need to imply the FDA serves pharma and not the public. Follow the money.
Your thinking is not correct. The FDA serves the wishes of the pharmas that they work for.
That article went off the rails about halfway through. However, using heat to treat tumors isn't new. There have been several experiments over the last few years on different cancers. If it works it's still several years away from approval.
A shelf offering? That doesn't mean immediate use, in fact the shares should be held until the share price would result in substantial revenue for the company.
Seems like Merck will bypass nwbo in favor of an alternative the fda will approve whether it works or not because the fda does what big pharma wants it to do.
Spell check strikes again. The worst improvement in internet history
Mercy doesn't have a weak hand. In fact they're holding all the cards. The fda will approve their drug without question whether the science is good or not.
This will be the end of nwbo if they don't report results and start getting the word out.
https://justthenews.com/politics-policy/health/moderna-announces-development-personalized-cancer-vaccine
I did. Moderna and Merck. Trial results by years end.
A Boy and his Dog.
I always think of the play Waiting for Godot when you mention waiting on your park bench for news of nwbo. Should be retitled waiting for nwbo or, better, waiting for the dough. Godot never shows up by the way.
Power hour is flatlined!
This implies at least 18 months more delay while a trial is conducted and the results analyzed. Probably longer. And MHRA was supposed to be the quickest path to approval.
Where do you think the focus of Adam Feurstein and his ilk will be? Which is the reason for waiting for a journal article. And waiting and waiting.
Yes, I do. My point is the secondary endpoints may present a problem as its possible they failed one, maybe two because they're based on pfs. We know pseudo progression would be the reason but without a journal article to fully explain it the AF's of the world would have a field day with the results. My real fear is that the journal article is being held up because they (the publication(s)) have issues with it as well.
Secondary endpoints. Not primary. We haven't seen the secondary end points results yet.
My guess is the first and second secondary ends points are problematic as they are both based on pfs. They need a presentation in a prestigious journal to explain those results. It has been speculated here that nwbo failed at least one of those end points. It's possible they failed both.
I'm pretty sure the only way is down until we get news. 50's next week.
The stockmarket is set to take a nosedive tomorrow on Walmarts after hours report today. Will be interesting to see if nwbo holds its own.
The share price has absolutely flatlined. First time I've seen that here
This resembles the last takedown and the one before that. Since we didn't even approach the one dollar mark this time I expect we'll see prices in the fifty cent range.
They are
Over 3 million share traded in the first hour. This could be a very high volume day.
I have a different theory. Accumulation of several hundred thousand shares by one buyer hitting the ask until their order is filled.
So you're saying there are 550,000 Brians in the world?
Even an approval wouldn't necessarily slow AF down. Witness amrn.
Victoria bitters is much better than Foster's. Foster's is for the tourists.
June 31st 2022
The S&P confirmed a bear market today.
On the highway to the danger zone
The company has painted itself into a corner. Without the journal a release of topline data will be an invitation for AF and others to attack them given that they've waited so long. We're hostage to a criteria the company set over which it has no control.
Adam was a colleague of Jim Kramer who once boasted in an interview that shorting a company's stock to the point of causing bankruptcy was the best result since there was no need to buy shares back. Completely ruthless. No one should defend the likes of Adam. He's not a journalist by any definition of that word.
St Judes is in Memphis. Of course, they're a children's research hospital so not directly related to the needs of nwbo but they do attract talented researchers and is a positive indicator of the talent pool available in Memphis.
Children was what popped into my mind when I read that sentence
AF continually attacked amrn because they used mineral oil in their placebo arm. He claimed it skewed the results by interfering with stating uptake in the placebo arm making vascepa look better. He continued that line of attack despite evidence to the contrary and disparaged vascepa by calling it fish oil. He was very effective in undermining the value of amarins stock.
So, what's my point? Calling him out is useless as is complaining to Stat news and the parent company. It's naive to believe they don't know what he does and would disapprove of it if only they knew because he's been at it for a long time with no real repercussions. They do know and turn a blind eye.
The only real antidote to his attacks is a strong and very vocal defense by the company's management. We're not seeing that and mgt has made it very clear they won't address his articles so we're just going to have to endure this nonsense until the company gets their journal article and releases top line data. If ASCO comes and goes and we're still waiting then expect another bear raid. Etc, ad infinitum ad nauseum.